
US Eli Lilly welcomes the new competition from low-cost insulin products from Novo Nordisk.
"I am pro any initiative that can power through and provide better value for patients," Eli Lilly CEO David Ricks told the tv network CNBC on Tuesday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app